Climb Bio, Inc. (CLYM)
| Market Cap | 436.60M +437.0% |
| Revenue (ttm) | n/a |
| Net Income | -59.85M |
| EPS | -0.90 |
| Shares Out | 47.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 260,932 |
| Open | 9.14 |
| Previous Close | 9.02 |
| Day's Range | 8.70 - 9.27 |
| 52-Week Range | 1.13 - 10.00 |
| Beta | -0.20 |
| Analysts | Strong Buy |
| Price Target | 16.82 (+84.03%) |
| Earnings Date | May 13, 2026 |
About CLYM
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company’s lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for CLYM stock is "Strong Buy." The 12-month stock price target is $16.82, which is an increase of 84.03% from the latest price.
News
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced ...
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
WELLESLEY HILLS, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, to...
Climb Bio Transcript: Leerink Global Healthcare Conference 2026
A year of foundational execution sets up multiple data readouts in 2026 for two lead antibody programs targeting B-cell mediated diseases. Key differentiators include broader B-cell targeting, subcutaneous formulations, and a novel APRIL-only antibody, with strong financial runway and ongoing business development focus.
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials...
Climb Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The company is advancing two antibody assets, budoprutug (anti-CD19) and CLYM116 (anti-APRIL), targeting immune-mediated diseases with multiple clinical readouts expected this year. Budoprutug has shown durable remissions in PMN, while CLYM116 demonstrates superior preclinical efficacy in IgAN.
Climb Bio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Multiple clinical readouts are expected in 2024 for two differentiated antibody programs targeting autoimmune diseases, with pivotal studies planned for PMN and IgAN. The company is well-funded into 2028 and is exploring further indication expansion for both assets.
Climb Bio to Present at Upcoming Investor Conferences
WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, tod...
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved r...
Climb Bio Transcript: Piper Sandler 37th Annual Healthcare Conference
Multiple data readouts for two monoclonal antibodies are expected in 2026, targeting PMN, ITP, SLE, and IgA nephropathy. Dose optimization and subQ formulations are key strategies, with a strong financial runway through 2027.
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, tod...
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical tri...
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced t...
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN)
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced t...
Climb Bio Transcript: Status Update
Climb 116, a next-generation anti-APRIL sweeper antibody, is advancing toward clinical trials for IgA nephropathy, aiming for best-in-class efficacy with deeper and more durable IgA suppression and less frequent dosing. Preclinical data show superior PK/PD versus first-generation agents, and global development is supported by a partnership with Mabwell.
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody
Climb Bio Transcript: Stifel Virtual Immunology and Inflammation Forum
The company is advancing monoclonal antibody programs for B-cell mediated diseases, with Budoprutug and CLYM116 targeting CD19 and APRIL, respectively. Multiple clinical trials are underway, with a cash runway through 2027 and key data readouts expected in 2026 and later this year.
Climb Bio Transcript: Baird Global Healthcare Conference 2025
Focused on monoclonal antibodies for B-cell-mediated diseases, the company advances Budo (CD19-targeted) and CLYM116 (anti-APRO) with a data-driven, indication-bucketed strategy. Early clinical data show strong efficacy in PMN, with multiple studies ongoing and key data readouts expected in the next 12–18 months.
Climb Bio Transcript: Cantor Global Healthcare Conference 2025
The company is advancing two main assets for immune-mediated diseases, focusing on CD19-targeted and anti-APRIL monoclonal antibodies. Early clinical data show strong efficacy and safety, with biomarker-driven strategies guiding development. Key priorities include execution, differentiation, and strategic indication selection.
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
WELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced ...
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced t...
Climb Bio to Present at Upcoming September 2025 Investor Conferences
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced t...
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the...
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards An...
Climb Bio Transcript: 24th Annual Needham Virtual Healthcare Conference
Focused on immune-mediated diseases, the company is advancing two B-cell-targeting assets—Budo (CD19 MAB) and CLYM116 (APRIL sweeper MAB)—with strong early clinical data in PMN and upcoming studies in ITP and SLE. Well-funded through 2027, key 2024 milestones include multiple trial initiations and preclinical data updates.